The antinociceptive effects of SCH-32615, a neutral endopeptidase (enkephalinase) inhibitor, microinjected into the periaqueductal, ventral medulla and amygdala

Brain Research

Volumn 520, Issue 1-2, 1990, Pages 123-130

  Al Rodhan, Nayef ^a   Chipkin, Richard ^a   Yaksh, Tony L ^a  

^a MAYO CLINIC   (United States)

Author keywords

Analgesia; Enkephalinase inhibition; Neutral endopeptidase; Opioid receptor; SCH 32615; Funaltrexamine

Indexed keywords

BETA FUNALTREXAMINE; ENKEPHALIN; METALLOPROTEINASE; MORPHINE; N (1 CARBOXY 2 PHENYLETHYL)PHENYLALANYL BETA ALANINE; NALOXONE; OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; HISTOLOGY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYGDALA; ANALGESICS; ANIMAL; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HEAT; MALE; MEDULLA OBLONGATA; MICROINJECTIONS; NEPRILYSIN; PAIN; PERIAQUEDUCTAL GRAY; RATS; RATS, INBRED STRAINS; REFLEX;

EID: 0025335560     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(90)91697-F     Document Type: Article

References (51)

1. Naloxone reversal of analgesia produced by brain stimulation in human
2. Antagonism of stimulation produced analgesia by naloxone, a narcotic antagonist
3. Evidence for the involvement of both the mu and delta opioid receptor subtypes in the antinociceptive effects of opiates in the ventromedial medulla (VMM)
4. Met-enkephalin-like immunoreactivity in rat forebrain and spinal cord using hydrogen peroxide and triton X-100. Ultrastructural study
5. Dose dependent reductions by naloxone of analgesia induced by cold water stress
6. Role of mu 1-opiate receptors in supraspinal opiate analgesia: a microinjection study
7. Effects of kelatorphan and other peptidase inhibitors on the in vitro and in vivo release for Met-enkephalin-like material from the rat spinal cord
8. Increased levels of met-enkephalin-like material in the CSF of anaesthetized cats after tooth pulp stimulation
9. Inhibitors of enkephalinase: the next generation of analgesics
10. 2] enkephalinamide analgesia in rats by thiorphan
11. Pharmacology of SCH 34826, an orally active enkephalinase inhibitor analgesic
12. 5-enkephalin (YGGFM) metabolism and on electroacupuncture antinociception
13. Dissociated effects of inhibitors of enkephalin-metabolizing peptidases or naloxone on various nociceptive responses
14. Expression of neutral endopeptidase (enkephalinase) in heterologous COS-1 cells
15. Role of the nucleus raphe magnus in opiate analgesia as studied by the microinjection technique in the rat
16. Inhibitory potency of various peptides on enkephalinase activity from mouse striatum
17. Regional distribution of met-enkephalin within the amygdaloid complex and bed nucleus of the stria terminalis
18. Identification of two related pentapeptides from the brain with potent opiate agonist activity
19. The periaqueductal gray: site of morphine analgesia and tolerance as shown by 2-way cross-tolerance between systemic and intracerebral injections
20. Facilitation de reactions nociceptives par la naloxone chez la souris et chez le rat
21. Comparison of antinociceptive action of morphine in the periaqueductal gray, medial and paramedial medulla in rat
22. Acute and chronic morphine modifies the in vivo release of methionine enkephalin-like immunoreactivity from the cat spinal cord and brain
23. Noxious stimuli and met-enkephalin release from nucleus reticularis gigantocellularis
24. Evaluation of the periaqueductal central gray (PAG) as a morphine specific locus of action and examination of morphine-induced and stimulation-produced analgesia at coincident PAG loci
25. Opioid and non opioid mechanisms of stress analgesia
26. Study of endogenous Tyr-Gly-Gly, a putative enkephalin metabolite, in mouse brain: validation of radioimmunoassay, localisation and effects of peptidase inhibitors
27. Steady-state level and turnover rate of the tripeptide Tyr-Gly-Gly as indexes of striatal enkephalin release in vivo and their reduction during pentobarbital anesthesia
28. Endogenous ooioid peptides: multiple agonists and receptors
29. High affinity enkephalin-degrading peptidase in brain is increased after morphine
30. Molecular cloning and amino acid sequence of rat enkephalinase
31. Selective protection of methionine enkephalin released from brain slices by enkephalinase inhibition
32. Elevation of aversive threshold in rats by intraamygdaloid injection of morphine sulfate
33. The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice
34. Metabolism of enkephalins and its inhibition
35. Analgesia and hyperreactivity produced by intracranial microinjections of morphine into the periaquaductal gray matter of the rat
36. Analgesia by enkephalins injected into the nucleus reticularis gigantocellularis gigantocellularis of rat medulla oblongata
37. Studies on the site of analgesic action of morphine by intracerebral microinjection
38. Immunohistochemical mapping of enkephalin containing cell bodies, fibers and nerve terminals in the brain stem of the rat
39. Autoradiographic comparison of the distribution of the neutral endopeptidase ‘enkephalinase’ and of μ and δ opioid receptors in rat brain
40. Immunohistochemical localization of enkephalin in rat forebrain
41. Effects of mu and delta selective opioid agonist in the guinea pig ileum preparation — differentiation into peptide and non peptide and non peptide classes using β-FNA
42. Systemic examination in the rat of brain sites sensitives to the direct application of morphine: observation of differential effect within the periaqueductal gray
43. Sites of action of opiates in production of analgesia
44. Factors governing the release of methionine enkephalin-like immunoreactivity from mesencephalon and spinal cord of the cat in vivo
45. 5)-enkephalin
46. Enkephalinergic projection from the ventro-media hypothalamic nucleus to the midbrain central gray matter in the rat: an immunocytochemical analysis
47. Nociception, enkephalin content of depeptidyl carboxypeptidase activity in brain of mice treated with exopeptidase inhibitors